Safety Outcomes Post Kidney Biopsy - Randomized Clinical Evaluation of Efficacy of Desmopressin
It is a randomized, multicenter, double-blind, placebo controlled, interventional clinical trial that will be conducted in Poland, in about 6 Hospital Nephrology Departments to evaluate the safety and effectiveness of desmopressin on the prevention of bleeding after percutaneous needle kidney biopsy in patients with rare and ultrarare glomerulonephritis.
• ≥ 18 years old
• Ability to provide Informed Consent
• Qualification by nephrologist to kidney biopsy in accordance to current standards
• Initial haemoglobin concentration \> 8g/dl and PLT count \>100 x103/μL
• Normal range of APTT and INR
• Blood pressure control defined as SBP\<160 mmHg
• Permitted antiplatelet/antithrombotic drugs: acetylsalicylic acid and heparin
• No inflammation at the point of biopsy needle insertion